This study tests whether adding a targeted drug called AZD5363 to the standard hormone therapy fulvestrant can slow the growth of advanced estrogen-receptor-positive (ER+) breast cancer. It involves 149 postmenopausal women whose cancer has worsened despite prior treatment with a…
Phase: PHASE1, PHASE2 • Sponsor: Velindre NHS Trust • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC